These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Autoimmune mechanisms and post-anesthetic hepatitis]. Duheille J; Montagne P Ann Anesthesiol Fr; 1976; 17(3):327-34. PubMed ID: 1078522 [TBL] [Abstract][Full Text] [Related]
24. [Grave and unusual results of the use of some psychopharmacological agents]. Quaranta A Recenti Prog Med; 1974 Sep; 57(3):240-68. PubMed ID: 4153212 [No Abstract] [Full Text] [Related]
25. [Possibility of differentiating viral and drug-induced hepatitis in tuberculous patients]. Fomin DKh; Gerasun BA; Gutarevich EA Sov Med; 1971 Jun; 34(6):74-8. PubMed ID: 5115455 [No Abstract] [Full Text] [Related]
26. Risk factors for anti tuberculous drugs induced hepatitis: a prospective survey from a chest clinic in a general hospital. Fauzi AR; Shah A; Rathor MY; Satwi S Med J Malaysia; 2004 Mar; 59(1):72-7. PubMed ID: 15535339 [TBL] [Abstract][Full Text] [Related]
27. Regarding "Management of antitubercular drug-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal". Anupa KC; Bista D Kathmandu Univ Med J (KUMJ); 2005; 3(3):310. PubMed ID: 18661667 [No Abstract] [Full Text] [Related]
28. Hepatitis due to anti-tuberculous drugs. Aggarwal NP Indian J Chest Dis Allied Sci; 1992; 34(4):231-2. PubMed ID: 1302758 [No Abstract] [Full Text] [Related]
30. Isoniazid-related fatal hepatitis. Salpeter SR West J Med; 1996 Nov; 165(5):323. PubMed ID: 8993215 [No Abstract] [Full Text] [Related]
31. Antituberculous therapy and acute liver failure. Caplin M; Thompson N; Hamilton M; McIntyre N; Burroughs A Lancet; 1995 May; 345(8958):1171. PubMed ID: 7786346 [No Abstract] [Full Text] [Related]
32. [Characteristics of drug-induced hepatitis in patients with tuberculosis]. Vil'derman AM Probl Tuberk; 1972; 50(5):59-63. PubMed ID: 4112966 [No Abstract] [Full Text] [Related]
33. [Hepatic toxicity of antitubercular agents: role of the HBS antigen carriers]. Flammang d'Ortho MP; Altman C; Cadranel J; Grange JD; Mayaud C Rev Pneumol Clin; 1990; 46(3):128-9. PubMed ID: 2237147 [No Abstract] [Full Text] [Related]
34. [Pathogenesis and treatment strategies of drug-induced liver injury]. Chen CW Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):726-8. PubMed ID: 24433798 [No Abstract] [Full Text] [Related]
38. [Hepatic jaundice in patients with pulmonary tuberculosis treated with various combinations of antitubercular drugs]. Kubiak Z Gruzlica; 1968 Oct; 36(11):1133-5. PubMed ID: 5710701 [No Abstract] [Full Text] [Related]
39. [Neuroleptic treatment of children and Australia antigen carrier state]. Bautsch A; Zajaczkowski J; Zyblikiewicz D Psychiatr Pol; 1976; 10(4):433-4. PubMed ID: 981418 [No Abstract] [Full Text] [Related]
40. [Liver and antitubercular drug therapy]. Viroglio AL; Piñeyro JO; Acosta A; Munaro N; Escarguel Malbrán J; Pérez JA Rev Fac Cienc Med Cordoba; 1974; 32(1):19-36. PubMed ID: 4458009 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]